Skip to main content
    E

    Eton Pharmaceuticals Inc (ETON)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $63.65
    -0.23 (-0.36%)

    Market Cap: $1.84B

    Last updated: Nov 17, 2026 at 4:30 PM ET

    Eton Pharmaceuticals Inc (ETON) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Eton Pharmaceuticals (ETON) has a market cap of $1.84B and an enterprise value of $1.81B. Revenue grew 100.61% over the last 12 months from the 12 months before. Its share count is up 6.57% from a year earlier.

    Total Valuation

    Enterprise value is 1.77% below the market cap, as cash exceeds debt.

    Market Cap$1.84B
    Enterprise Value$1.81B
    Latest price (Nov 17, 2026)$63.65

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.68% in the quarter ended Sep 30, 2026 and grew 5.19% a year over 2 years.

    Shares Outstanding28.66M
    Shares Change (YoY)+6.57%
    Shares Change (QoQ)+3.68%
    Share Count Growth (2Y CAGR)+5.19%

    Valuation Ratios

    Sales and book value multiples are 12.9x and 21.0x.

    P/E Ratio36.6x
    Forward P/E47.9x
    P/S Ratio12.9x
    Forward P/S10.2x
    P/B Ratio21.0x
    P/TBV Ratio42.8x
    P/FCF Ratio47.7x
    P/OCF Ratio48.0x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 38.7x EBITDA and 46.9x free cash flow.

    EV / Earnings36.3x
    EV / Sales12.8x
    EV / EBITDA38.7x
    EV / EBIT44.5x
    EV / FCF46.9x

    Price Statistics

    The stock is up 275.74% over 52 weeks and trades 14.77% above its 50-day average.

    Beta (1Y)0.56
    52-Week Change+275.74%
    1-Month Change+29.32%
    3-Month Change+3.53%
    6-Month Change+93.52%
    5-Year Change+805.90%
    Total Return (1Y)+275.74%
    Total Return (3Y CAGR)+161.92%
    Total Return (5Y CAGR)+69.78%
    Return vs SPY (1Y)+258.50%
    Max Drawdown (1Y)-26.82%
    Max Drawdown (3Y)-39.17%
    Sharpe Ratio (1Y)1.89
    Correlation with SPY (1Y)0.11
    50-Day Average$55.46
    200-Day Average$38.34
    52-Week Range$14.27 to $70.64
    RSI (14 Days)61.2
    Average Volume (20 Days)618.29K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.79x current liabilities, and total debt is 0.27x shareholder equity.

    Current Ratio1.79x
    Quick Ratio1.58x
    Debt / Equity0.27x
    Debt / EBITDA0.50x
    Debt / FCF0.60x

    Returns and Efficiency

    Return on invested capital is 36.99% over the last 12 months, against a 5-year average of -12.49%.

    Return on Equity (ROE)57.37%
    Return on Assets (ROA)31.71%
    Return on Invested Capital (ROIC)36.99%
    Return on Capital Employed (ROCE)39.43%
    ROE (5Y Average)-23.87%
    ROA (5Y Average)-11.22%
    ROIC (5Y Average)-12.49%
    Asset Turnover1.08x
    Inventory Turnover4.10x
    Receivables Turnover5.50x
    Cash Conversion Cycle26 days

    Scores

    ETON has an Altman Z-Score of 17.06, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score17.06
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $141.06M over the last 12 months.

    Revenue$141.06M
    Revenue Growth (YoY)+100.61%
    Gross Profit$97.55M
    Operating Income$40.69M
    Pretax Income$37.06M
    Net Income$49.86M
    EBITDA$46.33M
    EBIT$40.69M
    Reported EPS (TTM)$1.74

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 55.27% of the $157.27M in total assets.

    Cash and Equivalents$55.63M
    Total Debt$23.07M
    Net Cash$32.56M
    Net Cash Per Share$1.14
    Working Capital$42.69M
    Shareholder Equity$86.92M
    Book Value Per Share$3.03
    Tangible Book Value$42.64M
    Tangible Book Per Share$1.49
    Total Assets$157.27M
    Total Liabilities$70.35M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $142.00K of capital spending, operating cash flow left $38.21M of free cash flow.

    Operating Cash Flow$38.35M
    Capital Expenditures$142.00K
    Free Cash Flow$38.21M
    FCF Per Share$1.34
    Depreciation and Amortization$5.64M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 28.84%, against a 5-year average of -11.44%.

    Gross Margin69.15%
    Operating Margin28.84%
    Pretax Margin26.27%
    Net Margin35.35%
    EBITDA Margin32.84%
    EBIT Margin28.84%
    FCF Margin27.09%
    Gross Margin (5Y Average)66.89%
    Operating Margin (5Y Average)-11.44%
    Net Margin (5Y Average)-13.98%

    Growth

    Revenue grew 55.53% a year over 3 years.

    Revenue Growth (3Y CAGR)+55.53%
    Revenue Growth (5Y CAGR)+359.57%
    FCF Growth (3Y CAGR)+28.68%
    Book Value Per Share Growth (2Y CAGR)+27.14%

    Revenue and profit by year

    Dividends and Yields

    ETON does not pay a dividend. Its free cash flow yield is 2.09%.

    Earnings Yield2.73%
    FCF Yield2.09%
    Buyback Yield-0.01%
    Shareholder Yield-0.01%

    Peer Position

    Against 10 similar companies, ETON has the 2nd highest P/E.

    P/E Ratio36.6x vs 10.5x median
    P/S Ratio12.9x vs 1.8x median
    ROIC36.99% vs 6.30% median
    Revenue Growth (Trailing 4 Quarters, YoY)+100.61% vs +6.39% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 89.43% and EPS growth at 587.13% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+89.43%
    EPS Growth Forecast (2Y CAGR)+587.13%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ETON

    What is ETON's market cap?

    Eton Pharmaceuticals has a market cap of $1.84B. Its enterprise value, which adds debt and subtracts cash, is $1.81B.

    What is ETON's P/E ratio?

    Eton Pharmaceuticals has a trailing P/E ratio of 36.6x and a forward P/E of 47.9x.

    How many shares of ETON are outstanding?

    Eton Pharmaceuticals has 28.66M shares outstanding. The count is up 6.57% from a year earlier.

    Does ETON pay a dividend?

    No. Eton Pharmaceuticals does not pay a dividend.

    How much debt does ETON have?

    Eton Pharmaceuticals has $23.07M of total debt and $55.63M of cash and equivalents, a net cash position of $32.56M.